Sujet(s)
Anémie macrocytaire , Cytométrie en flux , Syndromes myélodysplasiques , Sujet âgé , Sujet âgé de 80 ans ou plus , Anémie macrocytaire/sang , Anémie macrocytaire/diagnostic , Diagnostic différentiel , Femelle , Cytométrie en flux/instrumentation , Cytométrie en flux/méthodes , Humains , Mâle , Adulte d'âge moyen , Syndromes myélodysplasiques/sang , Syndromes myélodysplasiques/diagnosticRÉSUMÉ
Management of systemic mastocytosis is an emerging challenge which requires a multidisciplinary diagnostic approach and personalized treatment strategy. Midostaurin can rapidly reduce the disease burden, also in cladribine refractory cases.
RÉSUMÉ
Systemic mastocytosis (SM) is a hematological malignancy characterized by extracutaneous infiltration by atypical mast cells. Together with indolent SM, aggressive SM, and mast cell leukemia, the World Health Organization (WHO) recognizes another major disease subgroup: SM with an associated hematological neoplasm, which is characterized by the presence of a concurrent neoplasm, more commonly, a chronic myelomonocytic leukemia. While KIT D816V is commonly regarded as the driver mutation, the clinical presentation of SM is extremely varied. Treatment of SM might not be simple, but now more specific therapies tailored toward prognostic subgroups of patients have been developed. Here, we report a detailed description of clinical management and biological features of a systemic mastocytocis case associated with multiple hematologic non-mast cell lineage diseases.